9th World Congress on Bioavailability and Bioequivalence (BABE 2018)

Starts On: 16/04/2018
Ends At: 18/04/2018
Country: United Arab Emirates
City: Dubai
Contact Email: ba.beasia@pharmaceuticalconferences.org
Contact Phone: +1-702-508-5200 Ext: 8122
Conference Website
1 Star2 Stars3 Stars4 Stars5 Stars (4 votes, average: 5.00 out of 5)
Loading...

About Conference

It’s glad to organize 9th World Congress on Bioavailability and Bioequivalence (BABE 2018) in UAE on April 16-18, 2018 at Dubai after a similar series of conferences in consecutive years at the USA over the last several years which met with great achievement in Business Conferencing.

9th World Congress on Bioavailability & Bioequivalence

Working under the theme “Unfolding Innovations in Bioequivalence/Bioavailability and Related Science” this unique international conference will opportunity to reach the largest assemblage of participants from the Pharmaceutical community to gather and share their insights and convey recent developments in the field of generic drug research and current challenges and possibilities in modelling a new drug and breakthroughs in drug development, Generic drug safety, Novel trends and advanced strategies involving bioavailability bioequivalence research. This is a true forum where ideas and discussion are driven by the participants and interaction with peers and others leads to fruitful outcomes.

BABE 2018 is a 3-day event offering the Exhibition, a venue to showcase the new and emerging technologies and have wider sessions involving  Keynote presentation, Oral, YRF ( student presentation), poster, e-poster presentations. World-renowned speakers and eminent delegates across the globe attending the conference, to share their valuable presentation on the most recent and advanced techniques, developments, and the newest updates are the prominent features of the conference.

Who to attend:

  • CEOs, CROs, Directors, Managers and research associates
  • Academic and Industrial Scientists
  • Regulatory and Clinical Scientists
  • Researchers, Education providers
  • Students and Postdoctoral Fellows
  • Government Agencies
  • Medical Practitioners
  • Clinical Pharmacologists
  • Clinical Toxicologists
  • Molecular and Cellular Pharmacologists

Why attend??

  • Exchange ideas and network with leading pharmaceutical scientists and clinicians and presenting cutting-edge discoveries, research, and new therapeutic drugs
  • Obtain a global roundup of Pharmaceutical research capabilities and opportunities

Call for Abstract

 - BABE 2018

9th World Congress on Bioavailability and Bioequivalence will be organized around the theme “Unfolding Innovations in Bioequivalence/Bioavailability and Related Science”

BABE 2018 is comprised of keynote and speakers sessions on latest cutting-edge research designed to offer comprehensive global discussions that address current issues in BABE 2018

 

 

Sessions/Tracks:

 

Track 1: Bioavailability and Bioequivalence

Bioavailability is the measuring of the extent of a therapeutically active medicine that reaches the systemic circulation and is consequently available at the site of action. Bioequivalence is the feature where if two drugs have identical active ingredients contains similar bioavailability and produce the same effect at the place of action.

The measurement of both bioavailability and bioequivalence is crucial to ensure constancy in standards of quality, efficacy &safety of Pharmaceutical dosage forms.

  • Track 1-1BA/BE Studies
  • Track 1-2Bioequivalence Cardiovascular Products
  • Track 1-3Bioequivalence Study Design
  • Track 1-4Bioequivalence Study Protocols
  • Track 1-5In Vitro Bioequivalence
  • Track 1-6universal bioavailability
  • Track 1-7Bioavailability Metrics
  • Track 1-8Waiver of invivo bioavailability

Track 2: Bioavailability Studies and Assessment

Conducting a Bioavailability study enables assessment of the impact of route of administration on BA and defines the absolute bioavailability of the drug released from the drug product. BA for a given formulation provides an assessment of the relative fraction of the orally administered dose that is absorbed into the systemic circulation. If the reference standard is an IV dose, it is referred as Absolute Bioavailability. If the reference standard is any other dosage form than IV, it is referred as Relative Bioavailability. Micro and Micronutrients play a vital role in bioavailability.

Bioavailability is a subcategory of pharmacological absorption. Bioavailability is generally assessed by finding the area under the plasma concentration-time curve. The factors affecting bioavailability are Pharmaceutics factors, physicochemical properties of the drug, Dosage form characteristics & Pharmaceutic Ingredients, Patient-related factors like age, Routes of administration (Parenteral, Rectal, Oral, and Topical)  etc. Topics under this track includes Nutrient Bioavailability, Absolute Bioavailability, Relative Bioavailability, Mineral Bioavailability- Micro and Macro, Vitamins Bioavailability, BA of Contaminants in Soils & Sediments, Drug Absorption and Distribution, Disposition studies, Drug Formulation and Dosage Forms, Product design- Considerations, Bioaccessibility Factor

  • Track 2-1Nutrient Bioavailability
  • Track 2-2Relative Bioavailability
  • Track 2-3Absolute Bioavailability
  • Track 2-4Mineral Bioavailability- Micro and Macro
  • Track 2-5Vitamins Bioavailability
  • Track 2-6BA of Contaminants In Soils & Sediments

Track 3: Bioequivalence Studies and Assessment

Bioequivalence studies are done for Early and late clinical trial formulations, Formulations used in clinical trial and stability studies,  if different Clinical trial formulations and to-be-marketed drug product When it comes to cost and productivity metrics, it’s often said that what gets measured gets done. Bioequivalence is determined based on the bioavailability of the innovator medicine versus the generic medicine. A typical outline for a bioequivalence study includes organization of the test and reference items on two events to volunteer subjects, with every organization isolated by a washout period. This Study involves parameters on (Cmax) and (AUC), Statistical evaluation.

Assessment of the bioequivalence of generic versions of certain reference drugs is complicated by the presence of endogenous levels of said compounds which cannot be distinguished from externally derived compound levels following drug administration. If unaccounted for, the presence of endogenous compound biases towards equivalence in bioequivalence studies of these drugs. Bioequivalence assessments may be complicated further as the disposition of the exogenous analog can be subject to various endogenous processes resulting in nonlinear pharmacokinetics. To overcome these inherent biases a number of different strategies have been employed.

  • Track 3-1Bioequivalence Protocols: In vitro-In vivo correlation
  • Track 3-2Dissolution Studies
  • Track 3-3Drug-release studies
  • Track 3-4Genetic Phenotyping
  • Track 3-5Response of clinical studies

Track 4: Drug Design and development: Challenges

Designing a new drug is a complex, multi-objective problem, demanding the synchronized optimization of target affinity, tissue exposure, formulation, toxicity and so on. Novel drug designers are constantly identifying innovative methods that can be used to improve their drug design. The challenge met nowadays is, how to integrate these multiple inputs and opinions to increase their effectiveness and accelerate drug discovery projects into the clinical outcomes, patient safety for the effective and sustained use of medicines.

  • Track 4-1Computer-Aided Drug Design
  • Track 4-2Rational Drug Design Approach
  • Track 4-3Novel Approach
  • Track 4-4Genetics in Drug Development
  • Track 4-5Topical Drug Development
0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *